JANX Stock Hits Record High on Prostate Cancer Study Data

Core Viewpoint - Shares of Janux Therapeutics surged 49% following the release of updated interim results from a phase Ib study evaluating JANX007 for advanced or metastatic prostate cancer [1][7]. Group 1: Study Results - The phase Ib study enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) who had a median of four prior therapies [2]. - All 16 treated patients achieved a 50% decline in prostate-specific antigen (PSA) levels after 12 weeks of treatment with JANX007 [3]. - Among the patients, 10 achieved a 90% reduction in PSA levels, with five experiencing a 99% decline [4]. Group 2: Treatment Efficacy - 75% of patients with a 50% PSA decline maintained this reduction for at least 12 weeks, while 50% of those with a 90% decline sustained it for the same duration [4]. - Based on these results, two once-weekly step-dose regimens of JANX007 have been selected for phase Ib expansion studies targeting previously treated mCRPC patients who have not received Pluvicto [5]. Group 3: Stock Performance - Following the announcement, Janux's shares reached an all-time high of $71.25, reflecting strong investor interest due to the impressive clinical performance of JANX007 [6]. - Year to date, Janux Therapeutics' shares have increased by 457.9%, contrasting with a 7.0% decline in the industry [8]. Group 4: Market Reaction - The positive update on JANX007 also led to a 13% rise in shares of Vir Biotechnology, which is developing a similar drug, VIR-5500 [11].